Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

242 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients.
Knights AJ, Nuber N, Thomson CW, de la Rosa O, Jäger E, Tiercy JM, van den Broek M, Pascolo S, Knuth A, Zippelius A. Knights AJ, et al. Among authors: zippelius a. Cancer Immunol Immunother. 2009 Mar;58(3):325-38. doi: 10.1007/s00262-008-0556-8. Epub 2008 Jul 29. Cancer Immunol Immunother. 2009. PMID: 18663444 Free PMC article.
Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells.
Müller P, Martin K, Theurich S, Schreiner J, Savic S, Terszowski G, Lardinois D, Heinzelmann-Schwarz VA, Schlaak M, Kvasnicka HM, Spagnoli G, Dirnhofer S, Speiser DE, von Bergwelt-Baildon M, Zippelius A. Müller P, et al. Among authors: zippelius a. Cancer Immunol Res. 2014 Aug;2(8):741-55. doi: 10.1158/2326-6066.CIR-13-0198. Epub 2014 Apr 21. Cancer Immunol Res. 2014. PMID: 24916470
Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer.
Sebastian M, Papachristofilou A, Weiss C, Früh M, Cathomas R, Hilbe W, Wehler T, Rippin G, Koch SD, Scheel B, Fotin-Mleczek M, Heidenreich R, Kallen KJ, Gnad-Vogt U, Zippelius A. Sebastian M, et al. Among authors: zippelius a. BMC Cancer. 2014 Oct 6;14:748. doi: 10.1186/1471-2407-14-748. BMC Cancer. 2014. PMID: 25288198 Free PMC article. Clinical Trial.
Cancer immunology - development of novel anti-cancer therapies.
Rothschild SI, Thommen DS, Moersig W, Müller P, Zippelius A. Rothschild SI, et al. Among authors: zippelius a. Swiss Med Wkly. 2015 Feb 4;145:w14066. doi: 10.4414/smw.2015.14066. eCollection 2015. Swiss Med Wkly. 2015. PMID: 25668078 Free article. Review.
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09.
Gautschi O, Mach N, Rothschild SI, Li Q, Stahel RA, Zippelius A, Cathomas R, Früh M, Betticher DC, Peters S, Rauch D, Feilchenfeldt J, Bubendorf L, Savic S, Jaggi R, Leibundgut EO, Largiadèr C, Brutsche M, Pilop C, Stalder L, Pless M, Ochsenbein AF; Swiss Group for Clinical Cancer Research. Gautschi O, et al. Among authors: zippelius a. Clin Lung Cancer. 2015 Sep;16(5):358-65. doi: 10.1016/j.cllc.2015.02.007. Epub 2015 Mar 5. Clin Lung Cancer. 2015. PMID: 25843489 Clinical Trial.
242 results